Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-29

I don't know what will happen to the share price but they must have discovered the commons list requirement will phase out June 2023,and by all intents and purposes the existing CE approved Eugeni platform can be sold then anyway.

So in essence a completely lost cause to chase a trial... Additionally the single geographic outliers detected in the trial must just have arrived in the interim report thay were meant to be used to kick off the commons list approval as well, and it was clearly decided then and there its going to be a waste of time and effort to end up at the same place without a wasteful trial. For the outliers to be isolated you would think it might be a testing method erorr of some sort?

No more trial required, additional $700k in the kitty, and CE approved Eugeni platform for June 2023 it seems.